Protocol Ledger

NCT03486457 · Phase III · COMPLETED

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

Interventional Phase III clinical trial protocol NCT03486457 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-10 Enrollment: 204 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03486457
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)204 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03486457
Protocol FieldVerified Registry Value
NCT IdentifierNCT03486457
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment204 participants (ACTUAL)
Registered Start Date2018-08-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI